JOSLIN DIABETES CENTER

Eli Lilly's Zepbound Demonstrates Superior Weight Loss Compared to Novo Nordisk's Wegovy in Head-to-Head Trial

6 months ago

• Eli Lilly's Zepbound (tirzepatide) led to a 20.2% average weight loss, significantly outperforming Wegovy (semaglutide) at 13.7% in a 72-week clinical trial. • The SURMOUNT-5 trial included overweight or obese adults without diabetes, showing Zepbound users experienced 47% more relative weight loss than Wegovy users. • Zepbound, a dual GIP and GLP-1 receptor agonist, helped 31.6% of participants achieve at least 25% body weight loss, compared to 16.1% with Wegovy. • The study's findings may influence treatment choices, with Zepbound potentially becoming a preferred option for greater weight loss outcomes, pending further data on tolerability.

NIH-Funded Study to Investigate Type 1 Diabetes' Impact on Children's Brain Development

8 months ago

• A nationwide longitudinal study, funded by a $2.7 million NIH grant, will explore the effects of type 1 diabetes on brain development in children. • The multi-site study will involve 12 research centers across the U.S. and recruit over 1,000 children newly diagnosed with type 1 diabetes. • Researchers aim to identify factors that may accelerate or mitigate the risk of brain-related complications in children with type 1 diabetes. • The study will use fMRI and collect data on academic performance, memory, attention, and neurobehavioral health to refine clinical guidelines.

Teva and IBM Watson Partner to Accelerate AI-Driven Drug Repurposing Initiative

9 years ago

• Teva Pharmaceuticals and IBM Watson Health have launched a collaborative project using artificial intelligence to identify new therapeutic applications for existing drug compounds. • The partnership leverages Watson's cognitive computing capabilities to analyze Teva's compound portfolio, with initial focus on developing abuse-deterrent opioids and extended-release schizophrenia treatments. • The collaboration extends to developing predictive models for chronic conditions like asthma, incorporating weather data to help prevent disease exacerbations through patient-centric digital solutions.